share_log

Senti Biosciences | 8-K: Current report

Senti Biosciences | 8-K: Current report

Senti Biosciences | 8-K：重大事件
美股sec公告 ·  04/27 05:00
牛牛AI助理已提取核心訊息
On April 23, 2024, Senti Biosciences Inc., a Delaware-incorporated biotechnology company, announced the resignation of its Chief Financial Officer, Treasurer, and Head of Corporate Development, Deborah Knobelman, Ph.D., effective May 3, 2024. Dr. Knobelman's departure is not due to any disagreements with the company's operations, policies, or practices. Following her resignation, Dr. Knobelman will enter into a consulting agreement with Senti Biosciences starting May 4, 2024, to assist with the transition of her responsibilities. She will receive a maximum payment of $60,000 for her services. Senti Biosciences is actively searching for an interim CFO and treasurer. The company plans to file the full Knobelman Consulting Agreement with its upcoming Quarterly Report on Form 10-Q for the quarter ending June 30, 2024. The report also includes forward-looking statements regarding the search for new financial leadership and acknowledges the risks and uncertainties inherent in the market and the company's SEC filings.
On April 23, 2024, Senti Biosciences Inc., a Delaware-incorporated biotechnology company, announced the resignation of its Chief Financial Officer, Treasurer, and Head of Corporate Development, Deborah Knobelman, Ph.D., effective May 3, 2024. Dr. Knobelman's departure is not due to any disagreements with the company's operations, policies, or practices. Following her resignation, Dr. Knobelman will enter into a consulting agreement with Senti Biosciences starting May 4, 2024, to assist with the transition of her responsibilities. She will receive a maximum payment of $60,000 for her services. Senti Biosciences is actively searching for an interim CFO and treasurer. The company plans to file the full Knobelman Consulting Agreement with its upcoming Quarterly Report on Form 10-Q for the quarter ending June 30, 2024. The report also includes forward-looking statements regarding the search for new financial leadership and acknowledges the risks and uncertainties inherent in the market and the company's SEC filings.
2024年4月23日，特拉華州註冊成立的生物技術公司森蒂生物科學公司宣佈其首席財務官、財務主管兼企業發展主管黛博拉·諾貝爾曼博士辭職，自2024年5月3日起生效。諾貝爾曼博士的離職不是由於與公司的運營、政策或做法有任何分歧。辭職後，諾貝爾曼博士將從2024年5月4日起與Senti Biosciences簽訂諮詢協議，以協助她移交職責。她的服務最高可獲得60,000美元的報酬。Senti Biosciences正在積極尋找臨時首席財務官和財務主管。該公司計劃在即將發佈的截至2024年6月30日的季度10-Q表季度報告中提交完整的Knobelman諮詢協議。該報告還包括有關尋找新的財務領導地位的前瞻性陳述，並承認了市場和公司向美國證券交易委員會提交的文件中固有的風險和不確定性。
2024年4月23日，特拉華州註冊成立的生物技術公司森蒂生物科學公司宣佈其首席財務官、財務主管兼企業發展主管黛博拉·諾貝爾曼博士辭職，自2024年5月3日起生效。諾貝爾曼博士的離職不是由於與公司的運營、政策或做法有任何分歧。辭職後，諾貝爾曼博士將從2024年5月4日起與Senti Biosciences簽訂諮詢協議，以協助她移交職責。她的服務最高可獲得60,000美元的報酬。Senti Biosciences正在積極尋找臨時首席財務官和財務主管。該公司計劃在即將發佈的截至2024年6月30日的季度10-Q表季度報告中提交完整的Knobelman諮詢協議。該報告還包括有關尋找新的財務領導地位的前瞻性陳述，並承認了市場和公司向美國證券交易委員會提交的文件中固有的風險和不確定性。
有用
沒用

該公告為獨立文件：

獨立文件1

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。